LACTOLOGY FOUNDATION

A10AC03 – Insulin (Pork), Intermediate-Acting: Toxicological and Lactological Monograph

1. ATC Classification and Pharmacological Profile

ATC code A10AC03 designates insulin (pork), intermediate-acting, within the Anatomical Therapeutic Chemical (ATC) classification subgroup A10AC, which includes intermediate-acting insulins and analogues for injection. Porcine insulin is an animal-derived peptide hormone historically used in the treatment of diabetes mellitus before recombinant human insulin became widely available. Although its clinical use has declined substantially, porcine insulin remains pharmacologically relevant because of its close structural similarity to human insulin and its established glucose-lowering activity.

Porcine insulin differs from human insulin by a single amino acid substitution at position B30 of the insulin B-chain, where alanine replaces threonine. This limited structural difference preserves its ability to bind to and activate the human insulin receptor, producing metabolic effects closely resembling those of endogenous human insulin.

The pharmacological activity of porcine insulin is mediated through insulin receptor activation and subsequent intracellular signaling pathways, including the phosphatidylinositol 3-kinase–Akt pathway. These mechanisms promote glucose uptake in skeletal muscle and adipose tissue, suppress hepatic gluconeogenesis and glycogenolysis, stimulate glycogen and protein synthesis, inhibit lipolysis, and facilitate intracellular potassium transport.

Intermediate-acting porcine insulin formulations are designed to prolong absorption following subcutaneous administration. Historically, delayed absorption has been achieved through formulation strategies involving protamine complexation or zinc-associated insulin suspensions. These modifications produce a more sustained glucose-lowering effect than soluble short-acting insulin, allowing intermediate basal insulin coverage.

The pharmacokinetic characteristics of intermediate-acting porcine insulin depend on the specific formulation, dose, injection site, tissue perfusion, physical activity, and individual physiological conditions. The onset and duration of activity are therefore variable, and a clinically recognizable peak of insulin action may contribute to fluctuations in blood glucose concentrations.

Following systemic absorption, porcine insulin undergoes receptor-mediated uptake and enzymatic degradation, predominantly involving the liver, kidneys, and peripheral tissues. Like endogenous human insulin, it is not metabolized through cytochrome P450 pathways.

The immunogenicity of porcine insulin is generally lower than that of bovine insulin because of its greater structural similarity to human insulin. Nevertheless, anti-insulin antibody formation and hypersensitivity reactions remain possible, particularly with older or less highly purified animal-derived formulations.

From a lactological perspective, the most important characteristics of porcine insulin are its peptide structure, susceptibility to gastrointestinal degradation, negligible expected oral systemic bioavailability, and pharmacological similarity to endogenous human insulin.

2. Toxicological Profile

The toxicological profile of intermediate-acting porcine insulin is primarily determined by excessive activation of physiological insulin-mediated metabolic processes. Hypoglycemia is the principal acute and dose-limiting toxicological effect, arising when insulin exposure exceeds the body's metabolic requirements.

Hypoglycemia may occur following excessive insulin administration, inadequate carbohydrate intake, delayed or omitted meals, increased physical activity, alcohol consumption, impaired renal or hepatic function, or changes in insulin sensitivity. Its clinical manifestations range from autonomic symptoms, including sweating, tremor, palpitations, hunger, and anxiety, to neuroglycopenic disturbances such as impaired concentration, confusion, behavioral changes, visual disturbances, seizures, loss of consciousness, and coma.

Severe or prolonged hypoglycemia may result in neurological injury and, exceptionally, death. Because intermediate-acting insulin formulations maintain prolonged absorption from the subcutaneous injection depot, excessive administration may produce recurrent or sustained hypoglycemia requiring extended clinical observation and repeated glucose supplementation.

Another important toxicodynamic effect is hypokalemia, resulting from insulin-mediated stimulation of potassium transport into cells. Clinically significant reductions in extracellular potassium concentrations may contribute to muscular weakness, electrocardiographic abnormalities, and cardiac arrhythmias, particularly following overdose.

The immunological characteristics of porcine insulin represent an additional toxicological consideration. Although purified porcine insulin generally exhibits relatively low immunogenicity, structural differences from human insulin may stimulate antibody production. Anti-insulin antibodies can occasionally alter insulin pharmacokinetics, contribute to glycemic variability, or produce clinically relevant insulin resistance.

Hypersensitivity reactions may include localized erythema, swelling, pruritus, or, rarely, systemic allergic manifestations. Some reactions may be associated with formulation excipients rather than the insulin molecule itself.

Repeated subcutaneous administration may cause lipohypertrophy or lipoatrophy at injection sites. These changes may interfere with predictable absorption and contribute to fluctuations in insulin activity. Weight gain and transient insulin-associated edema may also occur during treatment.

There is no established evidence that therapeutic porcine insulin produces clinically significant direct genotoxicity or intrinsic organ toxicity. Its principal toxicological hazards are therefore pharmacodynamic and immunological rather than related to conventional chemical toxicity.

During the postpartum period, maternal insulin requirements commonly decrease rapidly following the disappearance of placental hormone-mediated insulin resistance. Continued administration of pregnancy-level doses may consequently increase the risk of maternal hypoglycemia. This physiological transition is especially important in breastfeeding women, whose energy expenditure and glucose utilization may fluctuate with lactation.

3. Lactation Pharmacology and Breast-Milk Exposure

The lactation pharmacology of intermediate-acting porcine insulin requires consideration of its transfer into human breast milk, molecular stability within the infant gastrointestinal tract, and potential systemic or local biological effects following oral exposure.

Insulin is a naturally occurring constituent of human milk, and exogenously administered insulin can also be detected in breast milk. Importantly, limited direct evidence concerning porcine insulin transfer is available. In an experimental investigation involving seven lactating women with diabetes and ten without diabetes, intravenous administration of regular porcine insulin was associated with measurable changes in milk insulin concentrations. Peak milk insulin concentrations in the diabetic participants occurred approximately 30–50 minutes after administration. These findings demonstrate that exogenous porcine insulin can contribute to insulin detected in breast milk. However, the study investigated intravenously administered regular porcine insulin rather than subcutaneous intermediate-acting formulations and therefore cannot establish the milk concentration–time profile of A10AC03 preparations.

NCBI Bookshelf

Porcine insulin is a peptide hormone composed of two polypeptide chains connected by disulfide bonds. Its molecular structure makes it susceptible to gastrointestinal proteolysis, and systemic oral bioavailability of intact insulin is extremely low under ordinary physiological conditions.

Consequently, even when exogenous porcine insulin is present in breast milk, the quantity reaching the infant's systemic circulation in a biologically active form is expected to be negligible. This distinction between measurable milk concentrations and clinically relevant systemic exposure is fundamental to the lactological safety assessment.

Nevertheless, gastrointestinal degradation should not be interpreted as proof that all ingested insulin is immediately or completely destroyed. The neonatal gastrointestinal tract differs physiologically from that of adults, and milk-derived peptide hormones may retain local biological activity within the intestinal environment. Such activity does not necessarily imply systemic absorption or clinically significant glucose-lowering effects.

The potential local effects of porcine insulin on the infant gastrointestinal tract remain insufficiently characterized. Endogenous human milk insulin has been investigated for possible involvement in intestinal maturation and metabolic signaling, but the clinical relevance of these observations to maternally administered porcine insulin has not been established.

The structural similarity between porcine and human insulin supports the expectation of comparable receptor-mediated biological activity if intact insulin were systemically absorbed. However, the single amino acid difference also introduces a theoretical possibility of immunological recognition. There is currently insufficient evidence to establish that the low-level oral exposure potentially occurring during breastfeeding causes clinically significant sensitization or immune-mediated disease.

Quantitative pharmacokinetic parameters specifically applicable to intermediate-acting porcine insulin during lactation remain unavailable or insufficiently characterized. In particular, reliable values for the milk-to-plasma ratio, peak milk concentration, milk elimination half-life, and relative infant dose cannot be established from the available evidence.

Furthermore, conventional relative infant dose calculations have limited interpretative value for insulin because they do not account for its extremely low oral systemic bioavailability.

Overall, exposure of the breastfed infant to biologically active systemic porcine insulin is expected to be minimal, despite the possibility of measurable exogenous insulin in human milk.

4. Effects in the Breastfed Infant and on Lactation

The available clinical evidence does not establish a characteristic pattern of adverse effects in breastfed infants attributable to maternal treatment with intermediate-acting porcine insulin. Nevertheless, dedicated studies evaluating infant outcomes following exposure specifically to A10AC03 preparations are limited.

The principal theoretical pharmacodynamic concern is infant hypoglycemia resulting from systemic absorption of insulin ingested through breast milk. Such an effect is considered highly unlikely because intact insulin has negligible oral bioavailability and is extensively degraded within the gastrointestinal tract.

The broader clinical experience with maternal insulin therapy supports breastfeeding compatibility. The Drugs and Lactation Database (LactMed) states that mothers requiring insulin treatment may breastfeed and recognizes insulin as a normal constituent of human milk. However, these general findings should not be interpreted as definitive substance- and formulation-specific evidence for intermediate-acting porcine insulin.

NCBI Bookshelf

The immunological effects of porcine insulin exposure through breast milk require separate consideration. Although porcine insulin may induce anti-insulin antibodies following parenteral administration, the immunological consequences of oral exposure to very small quantities of the molecule are not equivalent to those associated with injection.

At present, there is no established clinical evidence demonstrating that maternal treatment with intermediate-acting porcine insulin causes allergic sensitization, autoimmune diabetes, or other immune-mediated disorders in breastfed infants. However, the absence of dedicated long-term studies prevents definitive conclusions regarding rare immunological outcomes.

With respect to lactation, insulin is an important physiological regulator of mammary gland metabolism. Adequate insulin signaling contributes to the metabolic processes required for milk synthesis and secretion.

Women with diabetes may experience delayed secretory activation, particularly when maternal glycemic control is inadequate or when additional obstetric and metabolic complications are present. Appropriate insulin treatment may support lactation indirectly by improving maternal metabolic stability.

There is no established evidence that therapeutic porcine insulin directly suppresses prolactin secretion, inhibits mammary gland function, or reduces established milk production.

Breastfeeding may influence maternal glucose homeostasis through the metabolic demands of milk synthesis. However, the magnitude of this effect varies considerably among individuals. Postpartum insulin requirements are frequently reduced, and lactation may contribute to further changes in glucose utilization, although breastfeeding does not consistently produce a substantial additional reduction in insulin requirements in every woman.

Accordingly, the principal clinically relevant concern during lactation is maternal hypoglycemia rather than direct toxicological exposure of the breastfed infant.

5. Lactological Safety Assessment and Clinical Recommendations

Intermediate-acting porcine insulin (A10AC03) is considered compatible with breastfeeding on pharmacological grounds, although direct formulation-specific clinical evidence remains limited.

The favorable lactological assessment is supported by the extensive gastrointestinal degradation of insulin, its negligible expected systemic oral bioavailability, the established physiological presence of insulin in human milk, and the broader clinical experience with maternal insulin treatment.

Unlike a complete absence of exposure, the available evidence indicates that exogenous porcine insulin can enter human milk. Nevertheless, measurable transfer does not imply clinically significant systemic exposure in the breastfed infant.

Breastfeeding should not ordinarily be interrupted solely because maternal treatment with intermediate-acting porcine insulin is necessary. Routine expression and disposal of breast milk are not indicated, and scheduling breastfeeding sessions around maternal insulin injections is unlikely to provide a meaningful safety benefit.

For healthy term infants, routine blood glucose monitoring is not required solely because the mother receives porcine insulin. Additional monitoring should be based on independent neonatal indications, including prematurity, illness, impaired feeding, or disorders affecting glucose homeostasis.

The management of premature or medically vulnerable infants should remain individualized. Although oral systemic absorption of insulin is expected to be minimal, the limited availability of direct evidence concerning intermediate-acting porcine insulin in these populations warrants appropriate clinical judgment.

Maternal treatment should focus on achieving stable glycemic control while minimizing hypoglycemia. Insulin requirements should be reassessed promptly after delivery and periodically throughout lactation. Dose adjustments should be guided by glucose monitoring, dietary intake, physical activity, renal and hepatic function, and individual metabolic responses.

Women should receive appropriate education regarding recognition and treatment of hypoglycemia, access to rapidly absorbable carbohydrates, adequate nutritional intake, and the potential for altered insulin requirements during breastfeeding.

The immunogenic potential of porcine insulin should also be considered. Although highly purified porcine insulin is generally less immunogenic than bovine insulin, antibody formation and hypersensitivity reactions remain possible. Unexplained changes in insulin requirements or glycemic variability may warrant clinical reassessment.

Where clinically appropriate, recombinant human insulin or a modern insulin analogue may be preferred because of greater contemporary clinical experience, standardized availability, and generally lower immunogenic potential. However, maternal use of porcine insulin does not itself constitute an indication for breastfeeding cessation or mandatory treatment substitution.

Switching between insulin preparations should be undertaken under medical supervision because differences in pharmacokinetic behavior and individual insulin sensitivity may necessitate dose adjustments.

The overall benefit-risk assessment favors continuation of effective maternal insulin therapy. Poorly controlled diabetes poses established risks to maternal health, whereas clinically significant systemic insulin exposure of the breastfed infant through milk is not expected.

Thus, intermediate-acting porcine insulin has a favorable anticipated lactological safety profile, with the principal limitations arising from insufficient formulation-specific clinical data rather than from an identified toxicological hazard to the breastfed infant.

6. Conclusion

Intermediate-acting porcine insulin, classified under ATC A10AC03, is an animal-derived insulin preparation with pharmacological activity closely resembling that of endogenous human insulin. Its toxicological profile is primarily characterized by excessive pharmacodynamic effects, particularly hypoglycemia and hypokalemia, while its potential immunogenicity represents an additional consideration.

From a lactological perspective, porcine insulin possesses favorable characteristics because of its peptide structure, susceptibility to gastrointestinal degradation, and negligible expected oral systemic bioavailability.

Limited direct evidence demonstrates that intravenously administered regular porcine insulin can contribute to measurable insulin concentrations in human milk. However, these findings cannot be directly extrapolated to the pharmacokinetic behavior of intermediate-acting subcutaneous formulations. Reliable quantitative data concerning breast-milk exposure specifically associated with A10AC03 remain insufficient.

No characteristic adverse-effect pattern has been established in breastfed infants exposed to maternal porcine insulin therapy. In particular, clinically significant infant hypoglycemia resulting from breast-milk exposure is not expected.

Nevertheless, the limited availability of dedicated studies prevents definitive conclusions concerning rare adverse reactions or long-term immunological outcomes.

Maternal insulin requirements may change substantially after delivery and during lactation. Therefore, individualized dose adjustment, appropriate glucose monitoring, adequate nutritional intake, and prevention of maternal hypoglycemia remain essential components of clinical management.

Routine interruption of breastfeeding, expression and disposal of breast milk, or infant laboratory surveillance is not indicated solely because of maternal treatment with intermediate-acting porcine insulin.

In conclusion, porcine intermediate-acting insulin (A10AC03) is considered compatible with breastfeeding and is associated with a very low anticipated lactational toxicological risk, although the direct substance- and formulation-specific evidence remains limited. Continuation of necessary maternal insulin therapy is supported, with clinical management directed toward maintaining maternal metabolic stability and minimizing treatment-related hypoglycemia.